Skip to main content

Nanogen Grabs License to Genetic Technologies Non-Coding DNA Patent

NEW YORK, April 23-Biochip company Nanogen has secured a license from the Australian firm Genetic Technologies Limited for access to non-coding DNA analysis patents, the companies said yesterday.


The license, which took effect April 12, is not exclusive, and is limited to human research and diagnostics.


Genetic Technologies said that Nanogen is paying the company cash and securities worth approximately A$620,000 (US $334,207) as an issue fee for the license.


Genetic Technologies recently granted a much broader license to Sequenom for its non-coding DNA patents, and is currently in discussions with other major United States biotech companies.


The company, which is based in Melbourne, boasts Australia's largest DNA paternity testing lab. In addition, it holds a range of international patents on non-coding (intron) DNA analysis and non-coding genomic mapping.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.